Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Empagliflozin in Patients Post Myocardial Infarction Rationale and Design of the EMPACT-MI Trial
Authors
Keywords
-
Journal
AMERICAN HEART JOURNAL
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-05-18
DOI
10.1016/j.ahj.2022.05.010
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT
- (2021) Prakriti Gaba et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction
- (2021) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
- (2020) Salim S. Virani et al. CIRCULATION
- Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF)
- (2020) Kevin Damman et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF
- (2020) Pardeep S. Jhund et al. CIRCULATION
- Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
- (2020) Francesco Cosentino et al. CIRCULATION
- Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial
- (2020) Milton Packer et al. CIRCULATION
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
- (2019) Eri T. Kato et al. CIRCULATION
- Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
- (2019) Stefan D. Anker et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
- (2018) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
- (2018) Eric J. Velazquez et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: A Swedish nationwide observational study
- (2017) Liyew Desta et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Acute myocardial infarction
- (2017) Grant W Reed et al. LANCET
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR® Research to Practice project
- (2017) Suzanne V Arnold et al. European Journal of Preventive Cardiology
- Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial
- (2016) David Fitchett et al. EUROPEAN HEART JOURNAL
- The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database
- (2016) Aldo P. Maggioni et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Trial Participation After Myocardial Infarction in a National Cardiovascular Data Registry
- (2014) Jacob A. Udell et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Key multiplicity issues in clinical drug development
- (2012) Alex Dmitrienko et al. STATISTICS IN MEDICINE
- The answer is 17 years, what is the question: understanding time lags in translational research
- (2011) Zoë Slote Morris et al. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE
- Do we need to adjudicate major clinical events?
- (2008) Christopher B Granger et al. Clinical Trials
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started